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DNA Ligase IV is responsible for sealing of double-
strand breaks (DSBs) during nonhomologous end-
joining (NHEJ). Inhibiting Ligase IV could result in
amassing of DSBs, thereby serving as a strategy
toward treatment of cancer. Here, we identify amole-
cule, SCR7 that inhibits joining of DSBs in cell-free
repair system. SCR7 blocks Ligase IV-mediated
joining by interfering with its DNA binding but not
that of T4 DNA Ligase or Ligase I. SCR7 inhibits
NHEJ in a Ligase IV-dependent manner within
cells, and activates the intrinsic apoptotic pathway.
More importantly, SCR7 impedes tumor progression
in mouse models and when coadministered with
DSB-inducing therapeutic modalities enhances their
sensitivity significantly. This inhibitor to target NHEJ
offers a strategy toward the treatment of cancer and
improvement of existing regimens.INTRODUCTION
Maintenance of genomic integrity is critical for the survival of
an organism. The genetic information is protected by processes
such as DNA repair, cell-cycle checkpoints, and apoptosis.
DSBs are considered as one of the most lethal types of DNA
damage within cells. Unrepaired DSBs can lead to chromosomal
rearrangements such as translocations, deletions, etc., resulting
in oncogenic transformations or cell death (Nambiar and Ragha-
van, 2011; Zhu et al., 2002). In higher eukaryotes, NHEJ is one of
the primary mechanisms of DSB repair and is active throughout
the cell cycle (Mao et al., 2008). During NHEJ, KU70/KU80 heter-
odimer binds to the DNA ends and recruits proteins such as
DNA-PKcs, Artemis, or Pol m or l to the repair site, resulting
in end-processing followed by Ligase IV, XRCC4, and XLF
complex-mediated ligation (Gostissa et al., 2011; Lieber, 2010;
Sharma and Raghavan, 2010).1474 Cell 151, 1474–1487, December 21, 2012 ª2012 Elsevier Inc.Besides Ligase IV, Ligase I and III are the other two ligases in
mammals (Ellenberger and Tomkinson, 2008). Ligase IV has
a multidomain architecture, consisting of a conserved ligase
domain at N terminus and a tandem BRCT domain at the C
terminus. The central catalytic domain comprises adenylation
and oligo-binding domains. It has been shown that N-terminal
DNA binding domain (DBD) of Ligase IV is crucial for its interac-
tion with DNA (Jayaram et al., 2008). However, unlike Ligase I,
there is limited information about the structure of DBD of Ligase
IV because it is yet to be crystallized (Pascal et al., 2004; Sibanda
et al., 2001).
Radio- and chemotherapy lead to the generation of DSBs
as intermediates during their action. NHEJ plays a major role
in providing resistance to cancer cells to these agents (Begg
et al., 2011). For example, KU70/KU80 is overexpressed in
breast and gastric cancers (Pucci et al., 2001). Higher expression
of DNA-PKcs has been correlated with radioresistance in oral
squamous cell carcinoma, lung carcinoma, and esophageal
cancer (Shintani et al., 2003; Sirze´n et al., 1999). Further, chemo-
resistant murine breast cancer cells exhibit reduced levels of
gH2AX foci upon g-radiation implying hyperactive DSB repair
(Zhang et al., 2010). Patients with mutations or lower levels of
Ligase IV are shown to be radiosensitive (Riballo et al., 1999).
In addition, polymorphisms in XRCC4 and Ligase IV have been
reported in breast cancers (Kuschel et al., 2002). Thus, downre-
gulation of NHEJ in cancer cells could lead to elevated sensitivity
to radiation and chemotherapeutic agents. This prompted us to
hypothesize that inhibition of NHEJ can be used as a means of
making cancer cells hypersensitive to radiations and other
DSB inducing agents. We chose Ligase IV as a potential target
because it is the crucial enzyme involved in NHEJ. Specifically,
we considered strategic targeting of the DBD of Ligase IV such
that it reduces its binding affinity for DSBs and deters its physi-
ological function.
In the present study, we identify SCR7 as a putative inhibitor
of NHEJ. SCR7 blocked end-joining (EJ) by interfering with
Ligase IV binding to DNA, thereby leading to accumulation of
DSBs within the cells, culminating into cytotoxicity. Further,
using various mouse models, we show that SCR7 impedes
Figure 1. Structural and Functional Characterization of SCR7
(A) Superimposition of DNA binding domains of human Ligase I (red) and Ligase IV (gray). The backbone atoms of the postulated DNA binding residues of Ligase I
and Ligase IV are colored in yellow and blue.
(B) A representative model of DBD of Ligase IV complexed with DSB. The side chains of amino acid residues that interact with the phosphate backbone of DNA
duplex are shown as sticks. Carbon atoms of DNA and side chain of substrate interacting residues from the DBD of Ligase IV are colored cyan and green,
respectively. The site of DSB is indicated by an arrow.
(C) Chemical structure of SCR7 [5,6-bis(benzylideneamino)-2-mercapto-pyrimidin-4-ol].
(D) Effect of SCR7 on joining of 50 compatible ends catalyzed by rat testicular extracts. ‘‘M’’ represents 50 bp ladder.
(E–G) Effect of SCR7 on EJ of 50-50 noncompatible (E), 50-30 noncompatible (F), and blunt (G) ends.
(H) Effect of Ligase I inhibitor, SCR5, on joining of 50 compatible ends.
(I) Agarose gel showing effect of SCR7 on plasmid based EJ. ‘‘M’’ is a 2 log DNA ladder.
In (D–I), the bar diagram represents quantification of respective EJ products from aminimum of three independent experiments and represented asmean ± SEM.
See also Figure S1 and Table S1.progression of tumor growth by activating intrinsic pathway of
apoptosis and thereby enhancing lifespan. Finally, we demon-
strate that treatment with SCR7 resulted in a significant increase
in the sensitivity of tumors toward radiation and etoposide.
RESULTS
Structure of the Complex Containing DBD of Human
Ligase IV Bound with DSBs
In absence of structural information for DBD of Ligase IV, a repre-
sentative 3D model of human Ligase IV (1–241 aa) was built byCa threading approach (I-TASSER) using multiple templates
arising from crystal structures of DBDs of other Ligases. DBD
of Ligase IV exhibited overall structural similarity with that of
Ligase I (RMSD = 1.6 A˚ for 190 Ca atoms) (Figure 1A). It is noted
that the conserved RLRLG and ELGVGD motif of the DBD of
Ligase I that interacts with nicked DNA (Pascal et al., 2004) is
conserved spatially in DBD of Ligase IV (DLKLG and AYGIKE in
Ligase IV), suggesting that these ligases might exhibit similar
contacts with the substrate DNA (Figure 1A). Multiple sequence
alignment of DBDs of other ligases also showed the conservation
of this motif (Figure S1A available online). Based on these clues,ell 151, 1474–1487, December 21, 2012 ª2012 Elsevier Inc. 1475
a DNA-containing DSB was docked with DBD of Ligase IV. Side
chains of Lys30, Arg32, Lys35, Arg69, Lys195, Gly197 (main
chain NH), Ser199, Gln201, Lys85, and Tyr82 from the DBD of
Ligase IV were found to be involved in hydrogen bonding with
anionic oxygen (Sp) of phosphates of DSB (Figure 1B).
Designing Potential Inhibitors of Ligase IV
A previous docking study on Ligase I with potential inhibitors had
identified the small molecule L189 to possess inhibitory action
against all three mammalian ligases (Chen et al., 2008). Its dock-
ing with the current homology modeled complex of Ligase IV
DBD and substrate DSBDNA duplex helped us in understanding
possible interactions that could be exploited in designing poten-
tial Ligase IV inhibitors. Examining the amino acid composition of
binding pocket together with multiple sequence alignment (Fig-
ure S1A) suggested that placing a substituent (ring C) emanating
from amine group meta to the SH group (ring A) such as benzal-
dehyde might increase its inhibitory action. In silico docking of
the modified compound indicated that addition of the ring C
could result in the loss of vital interactions involving conserved
basic residues viz., Lys35, Lys30 or Lys184, Arg188 of DBD of
Ligase IV, and anionic phosphates of DNA duplex, in addition
to other conserved residues (Figure S1B). The designed inhibi-
tors were then docked with DBD of Ligase IV, and their binding
energies estimated. The results pointed to a favorable binding
energy (29.14 kcal/mol) for the compound SCR7 as compared
to others (Figures 1C and S1C). Further, the inhibitors were
synthesized and characterized (Figures 1C and S1D).
SCR7 Inhibits End-Joining of Various DSBs
Previously, it was shown that testicular cell-free extracts are
proficient in NHEJ (Sathees and Raman, 1999; Sharma et al.,
2011). Thus, a cell-free repair assay system derived from rat
testes was used to study the effect of putative Ligase IV inhibi-
tors on NHEJ (Figures S1E and S1F) (Kumar et al., 2010; Sharma
et al., 2011). The results showed inhibition of end-joining of DSBs
(50 overhangs) by different compounds, and SCR7 was found to
be the most potent (Figures S1G and S1H). The purity of SCR7
was characterized byMS and LC-MS. Previously reported ligase
inhibitors, L189 (referred as SCR6) and L82 (inhibits Ligase I,
SCR5), were used as controls (Chen et al., 2008).
SCR7 inhibited EJ of [g-32P]ATP labeled double-stranded olig-
omeric DNA possessing 50 compatible, blunt, 50-50 or 50-30
noncompatible ends. Irrespective of the type of DSBs, SCR7 in-
hibited EJ mediated by testicular extracts in a concentration-
dependent manner from 50 mM (Figures 1D–1G). However,
when extracts from liver and kidney, possessing lower NHEJ
were used, SCR7 inhibited the joining even at 10 mM (Figures
S2A and S2B). On the other hand, SCR5 did not inhibit EJ cata-
lyzed by testicular extracts (Figure 1H). SCR7 could also inhibit
EJ of a plasmid DNA linearized with EcoRI, HindIII (50 overhangs)
or PstI (30 overhangs) (Figure 1I). Thus, SCR7 inhibited EJ irre-
spective of configuration of DSBs.
SCR7 Interferes with Ligase IV Activity and Inhibits
NHEJ
Ligase IV/XRCC4 complex can efficiently join compatible ends
(Gu et al., 2007), whereas joining of noncompatible termini1476 Cell 151, 1474–1487, December 21, 2012 ª2012 Elsevier Inc.requires additional proteins for end processing. To further con-
firm whether SCR7 interfered with Ligase IV activity, we used
purified Ligase IV/XRCC4 complex for joining assay (Figures
S2C, S2F, S2H, and 2A). Results showed that incubation with
increasing concentrations of SCR7 inhibited the formation of
multimers at 200mMandabove, unlikeSCR5 (Figures 2Band2C).
The effect of SCR7 on joining catalyzed by T4 DNA ligase and
mammalian Ligase I and III was investigated to test its specificity.
In the case of T4 DNA ligase, no reduction in the joining was
observed when compatible ends were used (Figure 2C). Further,
SCR7 did not affect joining catalyzed by Ligase I on nicked
substrates when equimolar concentration of protein was used
(Figures 2D and S2D and S2H). However, when purified Ligase
IIIa/XRCC1 was used, SCR7 inhibited the ligation of nicked
substrates (Figures 2D and S2E, S2H, and S2I). In order to further
validate the specificity of SCR7 with respect to NHEJ in cell-free
extracts, Ligase IV complementation was performed. Results
showed that the addition of SCR7 to the testicular extracts abro-
gated end-joining (Figure 2E, lane 3, and 2F). Interestingly, addi-
tion of purified Ligase IV/XRCC4 restored joining including that of
noncompatible ends (Figures 2E and 2F), establishing SCR7 as
an inhibitor of NHEJ. Studies using Circular dichroism (CD) spec-
troscopy and gel shift assay ruled out the possibility of SCR7
acting as an intercalating agent (Figures S3A–S3C).
SCR7 Binds to the DNA Binding Domain of Ligase IV and
Interferes with Its Binding to DSBs
Based on the above studies, we were interested in testing how
SCR7 interferes with NHEJ. It is known that KU70/KU80 complex
recruits and stabilizes Ligase IV/XRCC4 to the DNA ends (Nick
McElhinny et al., 2000). Results showed that Ligase IV/XRCC4
had more affinity to the KU70/KU80-coated ternary DNA com-
plex, consistent with previous reports (Figures 3A and 3B)
(Nick McElhinny et al., 2000). Addition of purified Ligase IV/
XRCC4 to the KU:DNA complex resulted in a supershift due to
its interaction with the KU bound DNA (Figures 3B, 3C, and
S3D). Interestingly, a dose-dependent reduction in supershift
was observed, upon addition of SCR7 indicating the unavail-
ability of Ligase IV to interact with DNA (Figures 3C, lanes 4–6,
and S3D, lanes 3–9). More importantly, addition of Ligase IV/
XRCC4 (30, 60, and 90 fmol) to the reaction led to a concentra-
tion-dependent supershift, confirming the specificity of SCR7 to
Ligase IV (Figure 3C, lanes 7–9).
In order to exclude the effect of the interacting partner, XRCC4
and determine the domain responsible for binding of SCR7 to
Ligase IV, we used purified Ligase IV and its DBD for CD spec-
troscopy (Figures 3D, S2G, and S2H). Results showed a clear
shift in the spectrum upon addition of SCR7 to Ligase IV or its
DBD, as compared to control (Figure 3D). Further, the shift
observed upon binding of SCR7 to DBD was directly propor-
tional to its concentration until 6 3 1018 M and remained
unchanged thereafter (Figure S3E). In addition, SCR7 binding
also resulted in a significant decrease in the intrinsic fluores-
cence of DBD, suggesting the quenching of aromatic residues
present at the interaction site (Figure 3E). Hence, these results
suggest specific binding of SCR7 to DBD of Ligase IV.
To examine themechanism bywhich SCR7 disrupts binding of
DBD of Ligase IV to the DNA duplex, we performed docking
Figure 2. Effect of SCR7 on DNA End-Joining Catalyzed by Purified Ligase IV/XRCC4 and Analysis of Its Specificity
(A) Western blot showing presence of Ligase IV/XRCC4 in purified fractions. W is an abbreviation of wash; 1 and 2 are different fractions.
(B) Comparison of effect of SCR5 and SCR7 on joining of 50 compatible ends catalyzed by purified Ligase IV/XRCC4 complex (60 fmol). For other details, refer to
Figure 1 legend.
(C) Bar diagram representing effect of SCR7 on EJ of 50 complementary ends catalyzed by purified Ligase IV/XRCC4 or T4 DNA ligase.
(D) Bar diagram showing effect of SCR7 on ligation of nicked DNA catalyzed by purified Ligase I or Ligase III.
(E) Complementation of SCR7 (150 mM)-mediated inhibition of NHEJ in testicular extracts by purified Ligase IV/XRCC4 (30, 60 and 120 fmol).
(F) Bar diagram representing quantification of the complementation experiment performed on 50-50 and 50-30 noncompatible ends.
In all panels quantification of EJ based on three independent experiments is represented as mean ± SEM. See also Figure S2.studies. A putative binding pocket defined by residues Arg69
and Asp193 to Gly197 (conserved DLKLG motif) within the
DBD was chosen. Three poses for SCR7 were generated (data
not shown), out of which a pose with favorable energy and
appropriate shape complementarity was docked with DBD
complexed with a DSB (Figure 3F). Atom groups OH, N, and
SH from the ring A of SCR7 engage in a hydrogen bond with
the side chain of Asp193, Arg69, and the backbone carbonyl of
Leu196 (Figure 3G). As a result of the binding of SCR7, hydrogen
bond interactions observed earlier, involving residues Arg69,
Lys195, Gly197 (of the DLKLG motif), Ser199, and Gln201 of
DBD and anionic oxygen of the phosphates of DNA duplexCwere completely lost (Figures 3G and 3H). Also, the aromatic
ring C of SCR7 sterically blocked the interactions that could arise
from the other highly conserved basic residues viz., Lys184 and
Arg188 (Figure 3F). Loss of these critical interactions seemingly
renders SCR7 as a competitive inhibitor, which is consistent
with above observations (Figures 3, S3D, and S3E).
SCR7 Inhibits NHEJ within Cells and Leads to
Generation of Unrepaired DSBs
An extrachromosomal assay system was used to evaluate the
effect of SCR7 on NHEJ inside the cells. I-SceI-induced DSBs
in pJS296 episome, which upon repair by NHEJ can restoreell 151, 1474–1487, December 21, 2012 ª2012 Elsevier Inc. 1477
Figure 3. Evaluation of SCR7 Binding to the DBD of Ligase IV and Its Effect on Binding to DSBs
(A) Western blot of KU70 and KU80 proteins in purified fractions. W is an abbreviation of wash; 1, 2, and 3 are different fractions.
(B) For Ligase IV/XRCC4 supershift, KU and oligomeric DNA were incubated followed by addition of Ligase IV/XRCC4 (60 fmol) and resolved on 1%–6% native
gradient PAGE.
(C) Analysis of effect of SCR7 (200, 500, and 700 mM) on Ligase IV/XRCC4 complex (60 fmol) binding to DNA. For complementation experiments, Ligase IV/
XRCC4 (30, 60, and 90 fmol) was added back to samples incubated with 700 mM of SCR7.
(D) CD spectroscopy to evaluate structural changes in Ligase IV and its DBD upon binding to SCR7. Ligase IV or DBD of Ligase IV were purified and confirmed by
western blotting. CD spectra were obtained at a wavelength of 200–260 nm.
(E) Intrinsic fluorescence spectra of DBD of Ligase IV, in the presence of SCR7 upon excitation at 280 nm. Fluorescent intensity is indicated in arbitrary units (A.U.).
(F) Electrostatic potential surface diagram of the DBD of Ligase IV docked with the DNA containing DSB and SCR7. Carbon atoms of DNA duplex and SCR7 are
colored cyan and pink, respectively. The region of occurrence of highly conserved basic residues (Lys184 and Arg188) beneath the ring C of SCR7 and DSB in the
DNA is depicted by an arrow.
(G) Postulated interactions of the bound SCR7 in the binding pocket of DBD of Ligase IV. The DBD of Ligase IV is represented as cartoon, whereas SCR7 is
shown as sticks. Hydrogen bond interactions are depicted as dashes.
(H) Comparison of interactions between the DBD of Ligase IV and duplex DNA containing DSB in presence of SCR7.
See also Figure S3.GFP expression (Figure 4A). Results showed GFP-positive re-
combinants upon expression of I-SceI confirming NHEJ (Fig-
ure 4A). Interestingly, upon addition of SCR7, a decrease in the
recombination, following normalization of transfection efficiency,1478 Cell 151, 1474–1487, December 21, 2012 ª2012 Elsevier Inc.was observed suggesting inhibition of NHEJ at the intracellular
level (Figure 4A).
Based on the above observations, we wondered whether the
inhibition of innate NHEJ could result in the accumulation of
Figure 4. Evaluation of the Effect and Specificity of SCR7 on NHEJ and Cytotoxicity within Cells
(A) Schematic representation of strategy used for measuring NHEJ inside the cells. pJS296 and I-SceI expression constructs were transfected along with
pcDNA3.1-RFP plasmid into HeLa cells followed by addition of SCR7 (0, 5, and 20 mM). Cells were harvested after 36 hr; GFP (measure of NHEJ) and RFP (control
for transfection) expressions were detected by flow cytometry. Peak indicated in green is cells transfected with pJS296 alone, black is pJS296 with I-SceI,
whereas red is pJS296with I-SceI alongwith SCR7. Bar diagram represents the percentage recombination frequency, indicating level of NHEJ after normalization
for transfection efficiency, based on multiple experiments.
(B) Immunofluorescence showing gH2AX foci in MCF7 cells after treatment with SCR7 (20, 40, and 100 mM, 24 hr) or siRNA against Ligase I, Ligase III and Ligase
IV. Either DMSO-treated cells or scrambled siRNA was used as control.
(C) Bar diagram showing quantification of gH2AX foci shown in (B). Aminimum of 50 cells were counted in each case. Reduction in expression of ligases following
siRNA transfection was confirmed by western blotting.
(D) Comparison of cytotoxicity induced by SCR7 on MCF7 and HCC1937 (BRCA1/) cells, as measured by MTT assay. DMSO served as vehicle control.
(E) DIC images of MCF7 cells treated with SCR7.
(F) Kill curves showing percentage cell proliferation with an increasing concentration of SCR7 (10, 50, 100, and 250 mM for 48 hr) on different cancer cell lines.
(G) Comparison of IC50 of SCR7 based on MTT assay in cancer cell lines.
(H) Analysis of cytotoxicity induced by SCR7 (48 hr) on Ligase IV/ (N114) and wild-type (Nalm6) cell lines as determined by MTT assay.
(I) Effect of SCR7 (50 mM) on cell proliferation after knockdown of Ligase IV and Ligase III in Nalm6 as determined by MTT assay. Immunoblotting confirmed the
knockdown.
(J) Comparison of SCR7 (50 mM)-induced cytotoxicity following knockdown or overexpression of Ligase IV in MCF7 cells. Western blotting confirmed the level of
Ligase IV expression.
In (A, C, D, H, I and J), the experiments shown were based on a minimum of three independent repeats and bar graph shows mean ± SEM (ns: not significant,
*p < 0.05, **p < 0.01, ***p < 0.001). See also Figure S4.unrepaired DSBs at the genome level. To test this, we treated
breast (MCF7) and cervical (HeLa) cancer cell lines with SCR7,
followed by immunofluorescence and western blotting studies,
by using anti-gH2AX. Results showed an increase in levels of
gH2AX foci and protein, indicative of unrepaired DSBs withinCcells (Figures 4B, 4C, and S4A–S4C). The number of foci
observed due to SCR7 was comparable to those generated
during siRNA knockdown of Ligase IV (Figures 4B, 4C, and
S4B). As a control, we used scrambled siRNA and siRNA against
Ligase I and III (Figures 4B, 4C, and S4B). However, similarell 151, 1474–1487, December 21, 2012 ª2012 Elsevier Inc. 1479
experiments on K562 cells did not yield any gH2AX foci, even at
highest concentrations of SCR7, possibly due to low expression
of Ligase IV (Figure S4A).
To exclude the possibility that SCR7 could generate DSBs
directly, independent of Ligase IV, N114 (Ligase IV/), and
Nalm6 (wild-type) cells were treated with SCR7 and assessed
for gH2AX levels by western blotting and immunofluorescence
(Figures S4D and S4E). Results showed that gH2AX expression
remained unchanged upon SCR7 treatment in Ligase IV/ cells,
whereas a significant increase was noted in case of Nalm6 cells
(Figure S4D). Both the cell lines showed substantial enhance-
ment in gH2AX and foci expression upon bleomycin treatment,
a known DSB inducing agent (Figures S4D and S4E). Overall,
these results suggest that SCR7 does not induce DSBs directly
to the genome and is Ligase IV dependent. Besides, upon incu-
bation of oligomeric dsDNA or supercoiled plasmid DNA with
increasing concentrations of SCR7, there was no evidence for
DNA breaks (Figure S4F). Thus, SCR7 interferes with NHEJ in
cells, leading to accumulation of unrepaired DSBs.
Cytotoxicity Induced by SCR7 Varies among Cancer
Cells
To evaluate whether accumulation of DSBs leads to cell
death upon SCR7 treatment, we performed a comparison of
cytotoxicity among various human cell lines derived from breast
(MCF7, T47D), cervical (HeLa), lung (A549), and ovarian (A2780)
cancers; fibrosarcoma (HT1080); and leukemia (K562, Reh,
Nalm6 and CEM), by using either MTT or trypan blue exclusion
assays. Results showed a dose-dependent decrease in cell
proliferation of MCF7, A549, and HeLa (Figures 4D–4G) with an
IC50 of 40, 34, and 44 mM, respectively, which was further
confirmed by DIC imaging in MCF7 (Figure 4E). T47D, A2780,
and HT1080 were also sensitive to SCR7, with an IC50 of 8.5,
120, and 10 mM, respectively (Figure 4G). In contrast, SCR7-
mediated cytotoxicity was limited when leukemic cell lines
were used, except for Nalm6, which showed an IC50 of 50 mM
(Figure 4G). Expression of Ligase IV in different cancer cells
could be correlated with their sensitivity to SCR7 (Figure S4G),
with an exception of T47D, which has low levels of Ligase IV.
This could be possibly due to a change in the proapoptotic to
antiapoptotic ratio, because of its aberrant BCL2 status (Zapata
et al., 1998).
To delineate the effect of SCR7 on homologous recombination
(HR) and NHEJ, an HR-deficient cell line, HCC1937 (BRCA1/)
was used. Results showed elevated sensitivity of this cell line to
SCR7, compared to its wild-type, MCF7, indicating that in the
absence of HR, DSBs generated due to blockage of Ligase IV
remain unrepaired leading to enhanced cell death (Figure 4D).
SCR7 Targets Ligase IV within the Cells to Induce
Cytotoxicity
To further investigate whether the cytotoxicity observed was
specific to Ligase IV inhibition, N114, and Nalm6 cells were
treated with increasing concentrations of SCR7. Results showed
that N114 remained unresponsive to SCR7, whereas Nalm6 ex-
hibited a dose-dependent increase in cytotoxicity (Figure 4H). To
confirm the observation, we knocked down Ligase IV by using
antisense plasmid in Nalm6, MCF7 and HeLa cells. Treatment1480 Cell 151, 1474–1487, December 21, 2012 ª2012 Elsevier Inc.of these cells with SCR7 led to the loss of sensitivity, compared
to sensitivity of mock transfected wild-type cells, establishing its
specificity to Ligase IV (Figures 4I, 4J, and S4H). Similarly, over-
expression of Ligase IV resulted in rescue of these cells from
SCR7 (Figures 4J and S4H, data not shown). Besides, knock-
down of Ligase III in Nalm6 did not result in significant loss of
cytotoxicity, suggesting that SCR7 exerts its effects by targeting
Ligase IV (Figure 4I).
It has been shown that blocking NHEJ can rescue interstrand
crosslink (ICL) repair defects in Fanconi Anemia deficient cells
(Adamo et al., 2010; Pace et al., 2010). We reasoned that
SCR7, being a NHEJ inhibitor, may suppress ICL sensitivity in
FANCD2-deficient cells. To test this, we treated human PD20
(FANCD2 deficient) cells with mitomycin C (MMC) and SCR7.
Results showed that treatment of MMC in PD20 resulted in
elevated sensitivity (Figure S4I). Interestingly, addition of MMC
along with SCR7 exhibited higher level of survival suggesting
that SCR7 could block NHEJ in FANCD2-deficient cells (Fig-
ure S4I). Elevated levels of chromosomal aberrations including
deletions were also observed in HeLa cells upon treatment
with SCR7 (Figures S4J and S4K).
SCR7 Prevents Progression of Tumor in Mice Resulting
in Increased Life Span
To assess the effect of SCR7 on tumor progression, we tested
different mice models. Results showed that SCR7 treatment
(10 mg/kg, six doses) significantly reduced breast adenocarci-
noma-induced tumor (Figure 5A). Untreated tumor animals
survived only for 52 days, whereas treated animals exhibited
4-fold increase in lifespan (Figure 5A). We also tested the
efficiency of SCR7 on Dalton’s lymphoma mouse model
(20 mg/kg, six doses) and found neither tumor regression nor
increase in lifespan (Figure 5B, data not shown).
Gross appearance of thigh tissues, liver, and spleen of control
and treated animals on the 25th and 45th day after tumor devel-
opment showed effect of SCR7 in a time-dependent manner
(Figure S5A). Histopathological examination showed tumor cell
proliferation in tumor controls, whereas a decrease was evident
upon SCR7 treatment (Figure 5C). Morphology of hepatocytes in
the treated groupwas comparable to that of normal animals (Fig-
ure 5C). Administration of SCR7 did not show any significant
difference in body weight (Figure S5B). Further, serum profile
of normal animals treated with SCR7 (10 mg/kg) displayed no
significant difference in the levels of alkaline phosphatase,
alanine aminotransferase, creatinine, and urea (Figure S5C).
Thus, treatment with SCR7 resulted in regression of tumors
with no obvious adverse effects. In addition, HPLC analysis of
serum following administration of SCR7 into mice (20 mg/kg)
showed bioavailability of 114 mg/ml and a t1/2 of 1 hr (Figures
S6A and S6B).
Further, via noninvasive luciferase imaging, the effect of SCR7
(six doses, 20 mg/kg) on tumor progression of fibrosarcoma
xenograft in real time was monitored for 2 weeks. Results
showed decreased photon emission in the SCR7-treated group
as compared to photon emission in the vehicle control (Fig-
ure 5D). We also noted increased disease-free survival in the
case of SCR7-treated mice (5/6 survived), as compared to that
in untreated controls where only one animal survived until the
Figure 5. Effect of SCR7 on Tumor Progression in Mice Models Bearing Various Tumors
(A) Effect of SCR7 on progression of solid tumor generated by breast adenocarcinoma cells. SCR7 (10 mg/kg, six doses) was intramuscularly injected from 12th
day of EAC injection, on every alternate day. Data shown is from three independent experiments containing 8 animals each. ‘‘Control’’ is mice injected with EAC
cells alone. ‘‘SCR7’’ is the mice bearing tumor treated with SCR7. Kaplan–Meier survival curves of SCR7-treated EAC mice.
(B) Kaplan–Meier survival curves of SCR7-treated (20mg/kg) Dalton’s lymphomamice. Data shown are from two independent batches of experiments containing
10 animals each. ‘‘Control’’ and ‘‘SCR7’’ are mice bearing tumor and treated with SCR7, respectively.
(C) Histopathology of tumor and liver of mice following SCR7 treatment after 25 and 45 days of tumor development. In all panels, ‘‘Normal’’ indicates mice with no
tumor, ‘‘Tumor’’ indicates mice induced with tumor, ‘‘Treated’’ indicates mice with tumors after treatment with SCR7.
(D and E) Luciferase imaging of SCR7 response in subcutaneous tumor models of fibrosarcoma (HT1080) and ovarian cancer (A2780). Nude mice (n = 10) were
implanted with either HT1080-Fluc2.tdTomato stable cells (D) or A2780-Fluc.tdTomato cells (E) and scanned for luciferase at days 7 and 14. Pseudocolor scale
bar represents photons captured by the CCD camera. Bar diagram shows comparison of tumor progression following treatment with SCR7.
(F) Flow cytometric analysis of CD3+ thymocytes and CD19+ bone marrow cells from SCR7 administered mice. Forward and side scatter along with the gated
population is also shown. Representative dot plots are shown in each case.
(G) The bar graph shows percentage of CD3+ population from thymocytes and CD19+ cells from bone marrow following treatment with SCR7. Numbers refer to
the percentage of each cell population in the gated lymphocytes. Data presented are derived from 14 and 17mice each for control and treated, respectively; in the
case of CD3+, it was 5 and 12 animals, respectively, for CD19+ cells.
(H) Bar graph showing lymphocyte population of bone marrow cells (n = 6) and splenocytes (n = 12) after 0 and 18 days of SCR7 administration (20 mg/kg, three
doses) acquired by flow cytometric analysis.
(I) PCR for detection of genomic rearrangement between variable and joining subexons during V(D)J recombination. Chromosomal DNA isolated from bone
marrow or thymus of control (n = 3) and SCR7-treated (n = 6) mice (20 mg/kg, three doses) were used for PCR. GAPDH was used as loading control (lower). Bar
graph represents efficiency of recombination.
(J) RT-PCR of VHJ558 region with the cDNA from bone marrow of SCR7-treated animals. HPRT was used as a loading control (lower). ‘‘M’’ is a molecular weight
ladder. Bar graph shows recombination efficiency.
In (A, B, D, E, G, H), bar graph shows mean ± SEM (ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001). See also Figure S5.
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14th day of treatment (Figure 5D). Antitumor activity of SCR7
was also evaluated in an ovarian cancer xenograft (six doses,
20 mg/kg) and a significant delay in tumor growth was observed
(Figure 5E). Noticeably, at day 14 the tumor size was not
reduced, despite a drastic reduction in the number of prolifer-
ating cells, suggesting that SCR7 could be a slower acting mole-
cule for certain cancers (Figure 5E). Taken together, our results
suggest that SCR7 can impede the tumor progression in
different animal models of cancer.
Effect of SCR7 on B and T Cell Development
Ligase IV plays a key role in rejoining coding ends during V(D)J
recombination through NHEJ, which raises the possibility that
SCR7 treatment on mice may affect lymphocyte development.
BALB/c mice administered with SCR7 (20 mg/kg, three doses)
were examined by flow cytometry for CD3+ (T cell marker) cells
in thymus, and CD19+ (B cell marker) cells in bone marrow
(Figures 5F and 5G). An 25% reduction in T cell population
was seen upon treatment with SCR7, whereas it was 40% in
case of B cells (Figures 5F and 5G). Understandably, the abso-
lute number of lymphocytes in spleen and bone marrow also
showed significant difference between control and treated
animals (Figure 5H).
In order to further assess the effect of SCR7 on V(D)J recom-
bination, genomic DNA and RNA were extracted from the bone
marrow of SCR7-treated mice. Results showed that treatment
with SCR7 led to a reduction in the efficiency of recombination
compared to that of controls, when genomic DNA was used
for PCR amplification of one of the junctions (Figure 5I). Cloning
and sequencing of the product confirmed its identity. Compa-
rable results were obtained when thymic samples were used
(Figure 5I). RT-PCR analysis also showed decreased levels of
VHJ558 recombination at the transcript level, further confirming
the effect of SCR7 on V(D)J recombination in lymphoid cells (Fig-
ure 5J). Importantly, defects in lymphocyte population (isolated
from spleen or bone marrow) upon SCR7 treatment were transi-
tory and restored following a recovery period of 18 days
(Figure 5H).
SCR7 Significantly Enhances the Sensitivity of Cancer
Cells to Radio- and Chemotherapeutic Agents
Because the effect of SCR7 was limited on tumors derived
from Dalton’s lymphoma (DLA) cells, we wondered whether
combining SCR7, along with existing treatment modalities that
induce DNA strand breaks, could enhance its sensitivity. To
test this, we irradiated mice bearing tumors either (2 Gy, two
doses) alone or in conjunction with SCR7 (20 mg/kg), whereas
untreated and SCR7-treated mice served as controls. A reduc-
tion in tumor growth was noted upon treatment with radiation
alone, whereas in conjunction with SCR7, it resulted in a sig-
nificant decrease in tumor growth both after 7 and 14 days of
treatment (Figure 6A). Further, we tested the effect of the chemo-
therapeutic drugs etoposide and 3-ABA (PARP inhibitor) on DLA
in the presence of SCR7. Interestingly, a substantial reduction in
tumor growth was seen when both SCR7 and etoposide were
used together, as opposed to either used alone (Figure 6B). In
contrast, the combination of PARP inhibitor and SCR7 did not
yield any appreciable effect on tumor progression, perhaps1482 Cell 151, 1474–1487, December 21, 2012 ª2012 Elsevier Inc.due to its inability to generate DSBs (Figure 6C). 3-ABA induced
cytotoxicity in the BRCA1/cell line, HCC1937, served as the
control for its bioactivity (Figure S6C). These results indicate
that SCR7 potentiates the cytotoxic effects of irradiation and
etoposide on tumor models in mice.
Based on the above study, we wondered whether SCR7 treat-
ment along with bleomycin could enhance the frequency of
DSBs in cancer cell lines. Results showed a higher number of
gH2AX foci per cell upon addition of increasing concentrations
of SCR7 in both MCF7 and HeLa cells, as compared to bleomy-
cin alone (Figures 6D and 6E). Overall, these results demon-
strate that SCR7 in combination with additional therapeutic
approaches like radiation or DSB inducing drugs can be used
as a more effective strategy for treatment of cancers.
SCR7Activates Intrinsic Pathway of Apoptosis to Induce
Cytotoxicity
The observed tumor regression in mice and increased cell
death in cancer cell lines by SCR7 prompted us to examine
the underlying mechanism. Immunohistochemistry (IHC) studies
showed that Ki67 (a cell proliferationmarker)-positive tumor cells
were substantially fewer in mice treated with SCR7 (10 mg/kg)
(Figure 7A). pATM was detected only in SCR7-treated tumor
sections, whereas basal level of ATM was observed both in
tumor and treated sections (Figure 7A). Expression of p21 (cell-
cycle regulator) and apoptotic markers such as BID and Cas-
pase 3 were also higher in treated tissues (Figure 7A). At the
25th day of SCR7 treatment (10 mg/kg), tumor tissues exhibited
TUNEL staining in the infiltrated tumor cells, in contrast to
untreated tumor tissues (Figure 7B) indicating DNA fragmenta-
tion, which is a hallmark of apoptosis.
To further investigate the downstream signaling events
associated with activation of apoptosis, we performed immuno-
blotting by using cell extracts prepared from SCR7 (20, 40 mM)-
treatedMCF7 cells. Results showed an increase in phosphoryla-
tion of ATM and activation of p53 (Figure 7C). A concomitant
decrease in MDM2 was also noted, resulting in activation of pro-
apoptotic proteins, PUMA and BAX (Figure 7C). Expression of
BCL2 decreased, whereas the levels of proapoptotic protein,
BAD, remained unchanged (Figure 7C). In addition, shorter
fragments of MCL1, which acts as proapoptotic protein, were
upregulated in a dose-dependent manner (Figure 7C). A dose-
dependent increase in PARP1, Caspase 3, and Caspase 9
cleavage was also seen (Figure 7C). Comparable results were
also obtained when Ehrlich ascites breast adenocarcinoma
(EAC), A549, and HeLa were used (Figures S7A–S7C). However,
K562 cells, which showed the least sensitivity to SCR7, did not
show any evidence for activation of apoptosis (Figure S7D).
Thus, the above results suggest that accumulation of DSBs
upon SCR7 treatment activates p53-mediated intrinsic pathway
of apoptosis.
DISCUSSION
Inhibition of NHEJ by SCR7 Leads to Accumulation of
DSBs and Cytotoxicity in Cancer Cells
Various attempts have been made to design inhibitors against
the proteins involved in DSB repair and DNA damage responses.
Figure 6. Evaluation of Effect of SCR7 on Tumor Progression in Mice following Treatment with Radiation and Chemotherapeutic Agents
(A–C) Comparison of tumor progression induced by DLA cells following treatment with SCR7 (20 mg/kg, three doses) for 14 days or in conjunction with
g-irradiation (two doses, 2 Gy, [A]), etoposide (10 mg/kg, [B]), and 3-aminobenzamide (10 mg/kg, [C]). Data shown is from two independent experiments con-
taining five animals each. ‘‘Control’’ indicatesmice injectedwith DLA, ‘‘SCR7,’’ themice bearing tumor treatedwith SCR7, ‘‘IR,’’ mice treatedwith g-radiation, and
‘‘IR+SCR7,’’ mice exposed to g-radiation and SCR7. ‘‘Etoposide’’ indicates mice treated with etoposide, ‘‘Etoposide+SCR7,’’ mice treated with etoposide and
SCR7. ‘‘3-ABA’’ indicates mice treated with 3-aminobenzamide and ‘‘3-ABA+SCR7,’’ mice treated with 3-aminobenzamide and SCR7.
(D and E) Immunofluorescence showing gH2AX foci within the MCF7 (D) or HeLa (E) following treatment with bleomycin alone or with SCR7 (20, 40 and 100 mM,
24 hr). DMSO served as the vehicle control. gH2AX foci formationwas detected as described in Figure 4. Bar diagram showing comparison of gH2AX foci inMCF7
(D) or HeLa (E) cells following treatment with bleomycin and SCR7. Data shown are from three independent experiments and in each case foci from aminimum of
50 cells were counted.
In (A–E), bar graph shows mean ± SEM (ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001). See also Figure S6.However, little is known about inhibitors against core NHEJ pro-
teins, such as KU70/80 complex, Artemis, Ligase IV/XRCC4,
Pol m, and Pol l. In the present study, we report an inhibitor
of NHEJ, which manifests its action by disrupting sealing of
DSBs, leading to accumulation of unrepaired breaks in the
genome. This results in activation of ATM, which phosphorylates
p53 and downregulates MDM2, culminating in activation of an
intrinsic pathway of apoptosis (Banin et al., 1998). Further, the
imbalance in the pro/antiapoptotic ratio within the cells leads
to activation of caspases, which results in PARP1 cleavage,
DNA fragmentation, and, eventually, cell death (Figure 7D).
Recent studies have suggested that Ligase IIIa/XRCC1 may
play a vital role in alternative-NHEJ (A-NHEJ), although its effi-Cciency and regulation inside cells still remains unclear (Sallmyr
et al., 2008). It is also known that the level of A-NHEJ increases
when either KU70/KU80 or Ligase IV/XRCC4 is inoperative (Sim-
sek and Jasin, 2010). Because we noted that SCR7 can also
inhibit ligation of nicks by Ligase IIIa/XRCC1, one would expect
some effect on A-NHEJ. Although knockdown of ligase IV de-
sensitized the cells toward SCR7, knockdown of Ligase III did
not show a similar effect, suggesting that effect of SCR7 was
majorly restricted to the former. Because Ligase IIIa/XRCC1 is
also involved in base excision repair, it needs to be verified
whether SCR7 has any effect on this pathway. Consistent with
this, the Ligase IV knockout cell line did not exhibit cytotoxicity
upon addition of SCR7. Further, overexpression of Ligase IV inell 151, 1474–1487, December 21, 2012 ª2012 Elsevier Inc. 1483
Figure 7. Mechanism of SCR7-Induced Cytotoxicity
(A) IHC for evaluation of cell proliferation, DNA repair, and apoptotic markers following treatment of SCR7 (10 mg/kg) in sections from mice bearing EAC tumors
(25 d). Antibodies against Ki67, ATM, pATM, p21, BID, and Caspase 3 were used.
(B) TUNEL assay showing DNA fragmentation of SCR7-treated (10 mg/kg) tumor tissues. Green color indicates methyl green stained nuclei, whereas brown
indicates DNA breaks stained with diaminobenzidine.
(C) Western blotting for apoptotic and DNA repair markers in SCR7-treated MCF7 cells. GAPDH was used as loading control.
(D) Model depicting role of SCR7 in the inhibition of NHEJ and activation of apoptotic pathway. SCR7 interferes with binding of Ligase IV/XRCC4 complex to the
DNA breaks bound by KU70/KU80 heterodimeric complex. Hence, unrepaired DNA breaks accumulate in the cell, activating DNA damage response followed by
induction of apoptosis by intrinsic pathway.
See also Figure S7.sensitive cells resulted in a loss of SCR7 effect, confirming
Ligase IV as the target of SCR7 within cells. The observed eleva-
tion in the survival of FANCD2-defective cells further validated
such a conclusion.
Inhibition of NHEJ as a Tool for Cancer Therapeutics
Among the four tumor models explored for the therapeutic
potential of SCR7, three were responsive. Interestingly, in one
of the models, a 4-fold increase in the lifespan was observed
and compared to controls. Morphological and histochemical
analysis in conjunction with liver and kidney function tests sug-1484 Cell 151, 1474–1487, December 21, 2012 ª2012 Elsevier Inc.gested that SCR7 treatment did not result in any adverse effects.
Being an inhibitor of one of the major DSB repair pathways,
SCR7 may not necessarily provide selective obliteration of
cancer cells. However, the faster proliferating nature of cancer
cells could be exploited particularly when administered to the
target cells. Cancer cells accumulate and tend to have more
innate DNA damage due to higher rates of replication. It is also
known that most cancer cells are defective in cell-cycle check-
points and have shorter repair times (Begg et al., 2011). Owing
to these facts, cancer cells can be more sensitive to SCR7 as
compared to surrounding normal tissues. This effect can be
further enhanced when repair inhibitors such as SCR7 are
utilized in conjunction with radio- or chemotherapy. Differential
protection of normal tissues could also be achieved by preferen-
tial uptake of drug in tumor cells due to extensive vascularization.
It has been shown that inactivation of Ligase IV in mice leads
to blockage of lymphopoiesis and V(D)J recombination (Frank
et al., 1998; Gao et al., 1998). Apart from lymphocyte develop-
mental defects, inactivation of Ligase IV in mice leads to late
embryonic lethality primarily due to massive apoptosis in neu-
ronal cells (Frank et al., 2000; Gao et al., 1998). It has also
been shown that Ligase IV deficiency leads to chromosomal
instability even in absence of DNA damaging agents and can
lead to neoplastic transformations (Ferguson et al., 2000; Frank
et al., 1998; Gao et al., 1998). However, such side effects were
not observed in mice treated with SCR7. This could be attributed
to lower concentrations, the number of doses, and the differen-
tial distribution of SCR7 inmice, in which genomic copy of Ligase
IV is intact, in contrast to knockout mice. It appears that the
stage at which the inhibitor is administered could also play
a key factor because we do not observe any developmental
defects associated with blockage of Ligase IV in 3- to 4-week-
old mice.
SCR7 had an effect on V(D)J recombination in developing
B and T cells, most likely due to a block in NHEJ, thus leading
to a significant reduction in overall lymphocyte population.
Interestingly, SCR7 did not lead to any permanent damage to
the immune system because completion of treatment regime
led to a restoration of the lymphocyte population. This was
also evident from the observed increase in the life span of
SCR7-treated mice with tumors. Noninvasive in vivo imaging of
SCR7-treated or untreated mice bearing different human tumor
xenografts also supports the idea that SCR7 does not interfere
with other physiological processes in mice.
Accumulation of unrepaired breaks along with modalities that
induce DSBs can be used as a strategy to further sensitize
cancer cells to treatment. Our results showed that when treated
along with SCR7, ionizing radiation (IR) and etoposide could
enhance tumor regression more efficiently. The observed slower
effect of SCR7 on A2780 tumor xenografts, further supports
such a conclusion. This strategy can be of immense importance,
particularly in case of resistant or unresponsive tumors, which
are known to have hyperactive DNA repair mechanism.
In conclusion, we show that inhibition of Ligase IV results in
the accumulation of DNA double-strand breaks, resulting in the
activation of apoptosis in cancer cells. The strategy employed
herein can be used for rational design of other inhibitors of Ligase
IV and other proteins associatedwith NHEJ. Based on the choice
of DSB repair pathway in a particular type of cancer, a target-
based therapy could be developed. Furthermore, the use of
DNA repair inhibitors along with existing chemo- and radiother-
apeutics could improve efficacy of treatment many fold.EXPERIMENTAL PROCEDURES
Purification of Ligases
Ligase I, Ligase IIIa/XRCC1, Ligase IV/XRCC4, and DBD of Ligase IV were
overexpressed in Escherichia coli and purified. See Extended Experimental
Procedures for details.CNHEJ Assay
NHEJ assay was performed as described with modifications (Kumar et al.,
2010; Sathees and Raman, 1999; Sharma et al., 2011) (Figures S1E and
S1F). Cell-free extracts (0.5 mg) from testis or purified Ligase IV/XRCC4 (60
fmol) was preincubated with appropriate concentrations of Ligase inhibitors
in NHEJ buffer (25 mM Tris-HCl, [pH 7.5], 75 mM NaCl, 10 mM MgCl2,
42.5 mM KCl, 0.025% Triton X-100, 100 mg/ml BSA, 10% PEG, and 5% glyc-
erol) in a reaction volume of 10 ml at 25C for 30 min. In case of reaction with
noncompatible ends, buffer was supplemented with deoxyribonucleotide
triphosphate (dNTPs). Because the compounds were dissolved in DMSO,
a corresponding concentration of DMSO was used in control reactions. After
preincubation with the inhibitors, [g-32P]ATP end-labeled oligomeric DNA
substrate (75 bp) possessing different termini (4 nM) was added to the mix
and incubated for 2 hr at 25C. Reactions were terminated by addition of
EDTA (10mM) and productswere purified by phenol-chloroform extraction fol-
lowed by precipitation. The reaction products were then resolved on 8%dena-
turing PAGE. The gel was dried and exposed and the signal was detected with
a PhosphorImager (FLA9000, Fuji, Japan) and analyzed with Multi Gauge
(V3.0) software.
For quantification of NHEJ products, the area corresponding to the band of
interest was selected in each lane, and the same size was selected in an area
with no band from each lane of the gel for subtracting background. Intensity
measured from each lane was indicated as photostimulated luminescence
(PSL) units and plotted.
Joining Assay with the Nicked Substrates
Nicked substrates were generated by annealing radioactively labeled MS68,
MS69, and MS70 and incubated with equimolar concentrations of Ligase I
(60 fmol) or Ligase IIIa/XRCC1 (60 fmol) for 1 hr at 25C. Joined products
were deproteinized and resolved on a 10% denaturing PAGE.
Complementation of SCR7 Inhibition with Purified Ligase IV
Inhibition of end-joining reaction was carried out as described above by incu-
bating testicular extracts with SCR7 (150 mM). Complementation experiment
was carried out by adding increasing concentrations of purified Ligase IV/
XRCC4 complex (30, 60, and 120 fmol) along with the oligomeric DNA
substrates (50 compatible and 50-50 noncompatible ends) to the SCR7-treated
extracts. Reactions were incubated for 2 hr at 25C; products were purified
and resolved on PAGE as described above.
Gel Mobility Shift Assay
For the binding studies, oligomeric DNA was incubated with KU or Ligase IV/
XRCC4 complex, and products were analyzed. See Extended Experimental
Procedures for details.
Modeling and Docking Studies
The 3D structure of SCR7 was built and energy minimized with Discovery
studio package (Discovery Studio 2.5. Accelrys, USA). Homolog model for
the DBD of Ligase IV was built with I-TASSER. See Extended Experimental
Procedures for details.
Intracellular NHEJ Assay
Intracellular NHEJ assay was performed as described earlier with modifica-
tions (Bennardo et al., 2008). HeLa cells (33 105) were seeded in 6-well plates.
Ten micrograms of NHEJ plasmid substrate pJS296 alone or with I-SceI
expression vector (20 mg) were transfected in absence or presence of
increasing concentrations of SCR7 (5 and 20 mM) with lipofectamine 2000
(Invitrogen) as per manufacturer’s recommendation. Equal concentration of
DMSO served as the vehicle control. pcDNA 3.1-RFP plasmid was transfected
in each case to determine the transfection efficiency.
Knockdown and Overexpression of Ligase IV
Ligase IV knockdown was performed with siRNA or antisense Ligase IV
plasmid by transfecting into MCF7, HeLa, and Nalm6 cells with oligofectamine
and lipofectamine (Invitrogen), respectively, whereas overexpression was per-
formed as per standard protocol. See Extended Experimental Procedures for
details.ell 151, 1474–1487, December 21, 2012 ª2012 Elsevier Inc. 1485
Determination of Effect of SCR7 in Combination with Radiation,
Etoposide, and 3-ABA
BALB/c mice were injected with DLA cells (0.25 3 106) intraperitoneally for
tumor development, after which two batches of animals were divided into
eight subgroups. Treatment was started after 5 days of DLA injection (d 0).
Group I served as tumor control (n = 10). Group II (IR, n = 5) and III (IR +
SCR7, n = 5) received two doses of radiation (2 Gy) on day 0 and 4. Besides
radiation, Group III also received six doses of SCR7 (20 mg/kg) on alternate
days from day 0. Group IV (etoposide, n = 5) and V (etoposide + SCR7,
n = 5) received three doses of etoposide (10 mg/kg) intraperitoneally on day
0, 4, and 8. In addition to etoposide, Group V animals also received six
doses of SCR7 (20 mg/kg) on alternate days from day 0. Group VI (3-ABA,
n = 5) and VII (3-ABA+SCR7, n = 5) received three doses of 3-Aminobenza-
mide (10 mg/kg) on days 0, 4, and 8. Group VII received six doses of
SCR7, as specified above. Group VIII (SCR7, n = 5) received six doses of
SCR7 alone (20 mg/kg) on alternate days (0, 2, 4, 6, 8, and 10) and served
as the control. Progression of tumor was monitored and data are presented
as a bar diagram. Error bars and levels of significance are indicated in respec-
tive figure legends.
Flow Cytometric Analysis of Mice Lymphocytes
BALB/c mice were injected with SCR7 and bone marrow, spleen, and thymus
were collected, stained for appropriate markers, and used for flow cytometry.
For details see Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and one table and can be found with this article online at http://dx.doi.
org/10.1016/j.cell.2012.11.054.
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